February 23, 2018 10:26 AM EST

Seeking greater gender diversity, Alnylam promotes four female leaders; Paul Hastings starts post-OncoMed career as CEO of stealthy Nkarta

Amber Tong

→ Consistent with a goal to foster gender diversity in its leadership ranks, Alnylam has promoted four female leaders to VP level. Kelly Bierly is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seeking greater gender diversity, Alnylam promotes four female leaders; Paul Hastings starts post-OncoMed career as CEO of stealthy Nkarta

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Seek­ing greater gen­der di­ver­si­ty, Al­ny­lam pro­motes four fe­male lead­ers; Paul Hast­ings starts post-On­coMed ca­reer as CEO of stealthy Nkar­ta

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Seeking greater gender diversity, Alnylam promotes four female leaders; Paul Hastings starts post-OncoMed career as CEO of stealthy Nkarta

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech